Skip to main content
Erschienen in: Diabetologia 7/2006

01.07.2006 | Article

What determines the cost-effectiveness of diabetes screening?

verfasst von: C. Glümer, M. Yuyun, S. Griffin, D. Farewell, D. Spiegelhalter, A. L. Kinmonth, N. J. Wareham

Erschienen in: Diabetologia | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The cost-effectiveness of screening for diabetes is unknown but has been modelled previously. None of these models has taken account of uncertainty. We aimed to describe these uncertainties in a model where the outcome was CHD risk.

Subjects and methods

Our model used population data from the Danish Inter99 study, and simulations were run in a theoretical population of 1,000,000 individuals. CHD risk was estimated using the UK Prospective Diabetes Study (UKPDS) risk engine, and risk reduction from published randomised clinical trials. Probabilistic sensitivity analysis was used to provide confidence intervals for modelled outputs. Uncertain parameter values were independently simulated from distributions derived from existing literature and deterministic sensitivity analysis performed using multiple model runs under different strategy choices and using extreme parameter estimates.

Results

In the least conservative model (low costs and multiplicative risk reduction for combined treatments), the 95% confidence interval of the incremental cost-effectiveness ratio varied from £23,300–82,000. The major contributors to this uncertainty were treatment risk reduction model parameters: the risk reduction for hypertension treatment and UKPDS risk model intercept. Overall cost-effectiveness ratio was not sensitive to decisions about which groups to screen, nor the costs of screening or treatment. It was strongly affected by assumptions about how treatments combine to reduce risk.

Conclusions/interpretation

Our model suggests that there is considerable uncertainty about whether or not screening for diabetes would be cost-effective. The most important but uncertain parameter is the effect of treatment. In addition to directly influencing current policy decisions, health care modelling can identify important unknown or uncertain parameters that may be the target of future research.
Literatur
1.
Zurück zum Zitat King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef
2.
Zurück zum Zitat Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617–621CrossRef Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617–621CrossRef
3.
Zurück zum Zitat Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for Type 2 diabetes—should it be now? Diabet Med 20:175–181PubMedCrossRef Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for Type 2 diabetes—should it be now? Diabet Med 20:175–181PubMedCrossRef
4.
Zurück zum Zitat Wareham NJ, Griffin SJ (2001) Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 322:986–988PubMedCrossRef Wareham NJ, Griffin SJ (2001) Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 322:986–988PubMedCrossRef
5.
Zurück zum Zitat Hofer TP, Vijan S, Hayward RA (2000) Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 16:822–833PubMedCrossRef Hofer TP, Vijan S, Hayward RA (2000) Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 16:822–833PubMedCrossRef
6.
Zurück zum Zitat Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M (2004) Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140:689–699PubMed Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M (2004) Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140:689–699PubMed
7.
Zurück zum Zitat Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479–500PubMedCrossRef Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479–500PubMedCrossRef
8.
Zurück zum Zitat Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548–551PubMedCrossRef Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548–551PubMedCrossRef
9.
Zurück zum Zitat Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 12:30–35PubMedCrossRef Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 12:30–35PubMedCrossRef
10.
Zurück zum Zitat Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101:671–679PubMedCrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101:671–679PubMedCrossRef
11.
Zurück zum Zitat Huang ES, Meigs JB, Singer DE (2001) The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633–642PubMedCrossRef Huang ES, Meigs JB, Singer DE (2001) The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633–642PubMedCrossRef
12.
Zurück zum Zitat Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:S6–S11PubMedCrossRef Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:S6–S11PubMedCrossRef
13.
Zurück zum Zitat Joint Formulary Committee (2002) British National Formulary. British Medical Association, and Royal Pharmaceutical Society of Great Britain, London Joint Formulary Committee (2002) British National Formulary. British Medical Association, and Royal Pharmaceutical Society of Great Britain, London
14.
Zurück zum Zitat Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V et al (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V et al (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
15.
Zurück zum Zitat Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
16.
Zurück zum Zitat Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a danish population: the inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a danish population: the inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef
17.
Zurück zum Zitat Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehabil 10:377–386PubMedCrossRef Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehabil 10:377–386PubMedCrossRef
18.
Zurück zum Zitat Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. 1999. World Health Organization, Geneva 1999. WHO/NCD/NCS/99.2 Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. 1999. World Health Organization, Geneva 1999. WHO/NCD/NCS/99.2
19.
Zurück zum Zitat CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention (1998) The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757–1763CrossRef CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention (1998) The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757–1763CrossRef
20.
Zurück zum Zitat Chen TH-H, Yen MF, Tung TH (2001) A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract 54:37–42CrossRef Chen TH-H, Yen MF, Tung TH (2001) A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract 54:37–42CrossRef
21.
Zurück zum Zitat Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735–744PubMedCrossRef Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735–744PubMedCrossRef
22.
Zurück zum Zitat Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
23.
Zurück zum Zitat Type 2-diabetes i almen praksis, en evidensbaseret vejledning. 2004. Dansk Selskab for Almen Medicin Type 2-diabetes i almen praksis, en evidensbaseret vejledning. 2004. Dansk Selskab for Almen Medicin
24.
Zurück zum Zitat American Diabetes Association (2006) Standards of medical care in diabetes—2006. Diabetes Care 29:S4–S42 American Diabetes Association (2006) Standards of medical care in diabetes—2006. Diabetes Care 29:S4–S42
25.
Zurück zum Zitat Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef
26.
Zurück zum Zitat Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef
Metadaten
Titel
What determines the cost-effectiveness of diabetes screening?
verfasst von
C. Glümer
M. Yuyun
S. Griffin
D. Farewell
D. Spiegelhalter
A. L. Kinmonth
N. J. Wareham
Publikationsdatum
01.07.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 7/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0248-x

Weitere Artikel der Ausgabe 7/2006

Diabetologia 7/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.